Skip to main content

Table 1 Clinical data of the five patients presented in the report

From: Ophthalmologic compromise following SARS-CoV-2 vaccinations

Patient

1

2

3

4

5

Age (y)

56

89

50

45

53

Sex

male

female

male

male

female

Vaccine brand

1. AZV

2. BPV

2. BPV

2. BPV

BPV

LVOD (d)

7

21

8

10

14

POD

herpetic keratitis, Iridocyclitis

right central vein occlusion, cataract, glaucoma

herpes uveitis iridocyclitis, COVID-19

non-arteritic AION

none

BCVA

0.02/1.0

hm/0.09

1.0/hm

1.0/1.0

1.0/1.0

Diagnosis

exacerbation of herpetic keratitis, iridocyclitis

anterior uveitis

retinal necrosis detachment vitritis

AION

ptosis after SAB ophthalmoparesis

Side

right

bilateral

left

left

left

Therapy

AV, ST

ST, antiglaucoma therapy

AV, ST, surgery

vasodilators antiplatelet agents

nm

Outcome (BCVA)

0.7/1.0 (1 m)

0.4/0.4 (4 m)

nm/nm

1.0/1.0

nm/nm

  1. AION Anterior, ischemic optic neuropath, AV Acyclovir, AZV AstraZeneca vaccine, BCVA Best corrected visual acuity, hm Hand movement, LVOD Latency between vaccination and ophthalmologic disease, nm Not mentioned,: previous ophthalmologic disease, SAB Subarachnoid bleeding, ST Steroids